Patient Preferences for Faster Home-Based Subcutaneous Immunoglobulin Infusion Therapy and the Effect on Adverse Events

Brent Rutland,1,* Carleton Southworth,2,* Jasmin Bosshard1 1Medical Affairs, KORU Medical Systems Inc., Mahwah, NJ, USA; 2American Research Partners LLC, South Bend, IN, USA*These authors contributed equally to this workCorrespondence: Jasmin Bosshard, KORU Medical Systems, 100 Corporate Drive, Mahwah, NJ, 07430, USA, Email [email protected]: Patients have expressed a preference for home-based subcutaneous immunoglobulin infusion therapy, often citing the time savings from not having to commute, as well as the flexible scheduling that home-based treatment provides. In this review of evidence, the opportunity to decrease time spent during infusions is explored, as well as the contrast between subcutaneous and intravenous infusion therapy. How decisions are made is also explored. Stakeholders include patients, their caregivers, and medical professionals supervising their care. Costs associated with various treatment options have been explored in the literature, in some depth. One element of cost that is often omitted, however, is the cost of time to patients and caregivers. A conclusion that there is a substantial opportunity to save patient and caregiver time is warranted. There is an opportunity to improve infusion protocols using existing devices. Evidence suggests that the mean savings per infusion is 38.94 minutes with optimized infusion protocols, saving more than one and one-half days of waking hours over the course of a year. More research in this domain is warranted.Keywords: SCIG, PIDD, home, adverse events, flow rates, patient preferences